BioPharma Resources

Drug Trial Radar · NCT05215340

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 740 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

740

Actual

Start

Mar 4, 2022

Primary completion

Mar 4, 2030

Study completion Mar 4, 2032

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
AstraZeneca; Merck Sharp & Dohme LLC
First posted
Jan 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer (NSCLC).

Conditions

  • Metastatic Non Small Cell Lung Cancer

Interventions

  • Datopotamab DeruxtecanDrug

    Dato-DXd will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.

  • PembrolizumabDrug

    Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival Based on Blinded Independent Central Review in Participants With Non-Squamous Histology Who Were Administered Dato-DXd in Combination With Pembrolizumab Compared With PembrolizumabTime frame: From randomization until disease progression or death (whichever occurs first), up to approximately 46 months
  2. Overall Survival (OS) in Participants With Non-Squamous Histology Who Were Administered Dato-DXd in Combination With Pembrolizumab Compared With PembrolizumabTime frame: From randomization until date of death due to any cause, up to approximately 72 months

Locations

234 sites in 28 countries. Site status is shown where the registry gives one.

  • Ironwood Cancer and Research Center

    Chandler, Arizona

  • UCLA HemOnc - Clinical Research Unit

    Los Angeles, California

  • Ridley-Tree Cancer Center

    Santa Barbara, California

  • PIH Health Whittier Hospital

    Whittier, California

  • The Oncology Institute of Hope and Innovation

    Whittier, California

  • Uch-Mhs D/B/A Memorial Health System

    Colorado Springs, Colorado

  • Johns Hopkins University

    Baltimore, Maryland

  • American Oncology Partners of Maryland

    Bethesda, Maryland

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana Farber Cancer Institute - Foxborough

    Foxborough, Massachusetts

  • DFCI - South Shore Hospital

    South Weymouth, Massachusetts

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire

  • Astera Cancer Care

    East Brunswick, New Jersey

  • Regional Cancer Care Associates LLC

    Freehold, New Jersey

  • Cooperman Barnabas Medical Center

    New Brunswick, New Jersey

  • The Valley Hospital

    Paramus, New Jersey

  • Montefiore Medical Center

    The Bronx, New York

  • Arizona Oncology NAHOA

    Irving, Texas

  • Cancer Care Center of Brevard

    Irving, Texas

  • Illinois Cancer Specialists

    Irving, Texas

  • Maryland Oncology Hematology

    Irving, Texas

  • Southern Cancer Center

    Irving, Texas

  • Texas Oncology - Northeast Texas

    Irving, Texas

  • Texas Oncology Gulf Coast

    Irving, Texas

  • Texas Oncology McAllen

    Irving, Texas

  • University of Texas Health Science Center San Antonio

    San Antonio, Texas

  • Utah Cancer Specialists

    Salt Lake City, Utah

  • Providence Regional Cancer System

    Lacey, Washington

  • VA Puget Sound Health Care System - VAPSHCS

    Seattle, Washington

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Centro de Investigaciones Medicas y Desarrollo LC S.R.L. (LC Investigacion)

    Buenos Aires, Argentina

  • Fundacion CENIT para la investigación en Neurociencias

    Ciudad Autonoma de Buenos Aire, Argentina

  • Hospital Privado de la Comunidad

    Mar del Plata, Argentina

  • Centro de Investigación Pergamino S. A.

    Pergamino, Argentina

  • Instituto de Oncología de Rosario

    Rosario, Argentina

  • Sanatorio Parque

    Rosario, Argentina

  • Sanatorio Británico de Rosario

    Rosario, Argentina

  • CER SAN JUAN - Centro Polivalente de Asistencia e Investigación Clínica

    San Juan, Argentina

  • Clinica Viedma SA

    Viedma, Argentina

Showing 40 of 234 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.